Bavarian Nordic A/S announced today that its US-based subsidiary BN ImmunoTherapeutics Inc. has received approval from the US Food and Drug Association (FDA) to start clinical trials with their breast cancer vaccine, MVA-BN®-HER-2*. Patient enrolment in a Phase I/II study in the US is expected to start as soon as possible.
